|
Clinical Question: In patient with Benign Prostatic
Hyperplasia (BPH), which is more safe and effective Tamsulosin or Alfuzosin?
Bottom Line: Both treatment regimens (Tamsulosin or
Alfuzosin) similarly improved the IPSS and Qmax did not alter sexual
function and were well tolerated.
Reference: J Int Med Res. 2005 Sep-Oct;33(5):562-73.A comparative
study on the safety and efficacy of tamsulosin and alfuzosin in the
management of symptomatic benign prostatic hyperplasia: a randomized
controlled clinical trial.Lapitan MC, Acepcion V, Mangubat J.National
Institutes of Health, University of the Philippines, Manila, Philippines.
Study Design: Randomized (double-blind, parallel-design
trial)
Synopsis: This randomized, double-blind, parallel-design
trial compared the efficacy and safety of tamsulosin and alfuzosin in 76 men
with symptomatic benign prostatic hyperplasia. Patients were randomized to
receive 0.2 mg tamsulosin once daily orally (n = 40) or 10 mg alfuzosin once
daily orally (n = 36), and changes in the International Prostate Symptom
Score (IPSS), maximal urinary flow rate (Qmax) and the Danish prostatic
symptom sexual function score and morbidity rates were compared after 8
weeks of treatment. There was a mean overall decrease in the IPSS, with no
significant difference between the treatment groups. There was an overall
increase in the Qmax, which again was similar in the two groups. There was
no significant change in the sexual function scores in either group. The
incidence of adverse events was similar for tamsulosin (25%) and alfuzosin
(19.4%) therapy.
|